Subscribe
court-istock-521811810-berezko
berezko / iStockphoto.com
26 September 2018Americas

AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation

The inter partes review (IPR) process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Hatch-Waxman amendment: a Hobson’s choice
8 August 2018   If enacted by Congress, the proposed amendment to the Hatch-Waxman Act would spell trouble for generic pharmaceutical companies seeking to take on brand competitors in patent litigation, says Janine Carlan of Arent Fox.
Americas
Senator proposes Hatch-Waxman change to boost generic development
15 June 2018   US Senator Orrin Hatch has proposed an amendment to the Hatch-Waxman Act to “restore the careful balance” the act struck to incentivise generic drug development.
Biotechnology
Roche loses appeal to block market entry of rival cancer drug
7 July 2020   A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Hatch-Waxman amendment: a Hobson’s choice
8 August 2018   If enacted by Congress, the proposed amendment to the Hatch-Waxman Act would spell trouble for generic pharmaceutical companies seeking to take on brand competitors in patent litigation, says Janine Carlan of Arent Fox.
Americas
Senator proposes Hatch-Waxman change to boost generic development
15 June 2018   US Senator Orrin Hatch has proposed an amendment to the Hatch-Waxman Act to “restore the careful balance” the act struck to incentivise generic drug development.
Biotechnology
Roche loses appeal to block market entry of rival cancer drug
7 July 2020   A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.

More on this story

Americas
Hatch-Waxman amendment: a Hobson’s choice
8 August 2018   If enacted by Congress, the proposed amendment to the Hatch-Waxman Act would spell trouble for generic pharmaceutical companies seeking to take on brand competitors in patent litigation, says Janine Carlan of Arent Fox.
Americas
Senator proposes Hatch-Waxman change to boost generic development
15 June 2018   US Senator Orrin Hatch has proposed an amendment to the Hatch-Waxman Act to “restore the careful balance” the act struck to incentivise generic drug development.
Biotechnology
Roche loses appeal to block market entry of rival cancer drug
7 July 2020   A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent